scispace - formally typeset
A

Amy Berson

Researcher at Hoffmann-La Roche

Publications -  8
Citations -  1127

Amy Berson is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Antibody & Fucose. The author has an hindex of 6, co-authored 8 publications receiving 1080 citations.

Papers
More filters
Journal ArticleDOI

Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice.

TL;DR: P2X3 is critical for peripheral pain responses and afferent pathways controlling urinary bladder volume reflexes and may have therapeutic potential in the treatment of disorders of urine storage and voiding such as overactive bladder.
Journal ArticleDOI

Control of P2X2 Channel Permeability by the Cytosolic Domain

TL;DR: Attention is focused on specific residues of P2X2 channel cytoplasmic domains as determinants of permeation in a state-specific manner to determine that two specific amino acid residues in the cytosolic tail domain govern this difference in behavior between the two orthologous channels.
Journal ArticleDOI

Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: Lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice

TL;DR: The results suggest that NTR1 does not play a major role in the control of basal thermoregulation, nociception or psychomotor stimulation in mice (barring possible developmental plasticity), and does mediate these behavioral responses to NT agonists, and may play a role inThe potential antipsychotic effects of these agonists.
Patent

Methods for assessing emphysema

TL;DR: In this article, the efficacy of therapeutic drug candidates for the treatment of emphysema and/or COPD is evaluated, by determining biomarkers selected from the group SpB, desmosine, VEGF3 IGFBP2, MMP12, TIMPl,MMP9, Crabp2, Rbpl, Cyp26al, Tgm2, Timρ3, Adaml7, Serpinal, Slpi, Collal, EIn, TGFβl,TGFβ-RII, Sftpal, Csf2
Journal ArticleDOI

A Novel CCR5-Specific Pharmacodynamic Assay in Whole Blood Using Phosphoflow Cytometry Highlights Different Ligand-Dependent Responses but Similar Properties of Antagonists in CD8+ and CD4+ T Lymphocytes

TL;DR: A novel method to assay the pharmacodynamic (PD) properties of small-molecule and antibody inhibitors of CCR5 ligand-induced activation by measuring phosphorylation of serine residue 349 in the cytoplasmic tail of human C CR5 using phosphoflow cytometry in whole blood is reported.